Abstract
Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.
| Original language | English (US) |
|---|---|
| Article number | 552 |
| Journal | BMC Cancer |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jun 7 2019 |
| Externally published | Yes |
Fingerprint
Keywords
- Cost-effectiveness
- Economic evaluation
- Net benefit regression
ASJC Scopus subject areas
- Oncology
- Genetics
- Cancer Research
Cite this
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments : An example from the Canadian Cancer Trials Group CO.17 trial. / Hoch, Jeffrey S; Hay, Annette; Isaranuwatchai, Wanrudee; Thavorn, Kednapa; Leighl, Natasha B.; Tu, Dongsheng; Trenaman, Logan; Dewa, Carolyn S; O'Callaghan, Chris; Pater, Joseph; Jonker, Derek; Chen, Bingshu E.; Mittmann, Nicole.
In: BMC Cancer, Vol. 19, No. 1, 552, 07.06.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments
T2 - An example from the Canadian Cancer Trials Group CO.17 trial
AU - Hoch, Jeffrey S
AU - Hay, Annette
AU - Isaranuwatchai, Wanrudee
AU - Thavorn, Kednapa
AU - Leighl, Natasha B.
AU - Tu, Dongsheng
AU - Trenaman, Logan
AU - Dewa, Carolyn S
AU - O'Callaghan, Chris
AU - Pater, Joseph
AU - Jonker, Derek
AU - Chen, Bingshu E.
AU - Mittmann, Nicole
PY - 2019/6/7
Y1 - 2019/6/7
N2 - Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.
AB - Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.
KW - Cost-effectiveness
KW - Economic evaluation
KW - Net benefit regression
UR - http://www.scopus.com/inward/record.url?scp=85066861264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066861264&partnerID=8YFLogxK
U2 - 10.1186/s12885-019-5779-x
DO - 10.1186/s12885-019-5779-x
M3 - Article
C2 - 31174497
AN - SCOPUS:85066861264
VL - 19
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
IS - 1
M1 - 552
ER -